publication date: Dec. 2, 2016

In Brief Tuveson Heads Cold Spring Harbor; COH, TGen Form Collaboration

DAVID TUVESON was named director of the NCI-designated Cold Spring Harbor Laboratory Cancer Center, taking over from Bruce Stillman who has served in that capacity for 25 years.

Stillman will remain CSHL president and CEO, and will maintain a research laboratory focusing on DNA replication and genome inheritance.

Tuveson’s research and clinical focus is pancreatic cancer. He has pioneered a pancreatic organoid technology.

Tuveson is the Roy J. Zuckerberg Professor of Cancer Research at CSHL, the head of the Lustgarten Foundation Pancreatic Cancer Research Laboratory at CSHL, and the Lustgarten Foundation’s director of research. In 2012,

Tuveson directed the Cancer Therapeutics Initiative within CSHL’s Cancer Center. He continues to practice medical oncology with an adjunct appointment at Memorial Sloan Kettering Cancer Center and a clinical affiliation at Northwell Health. He serves on the scientific advisory council for Stand up to Cancer and the SAB of the Georg Speyer Haus.

His honors include the Rita Allen Foundation Scholar Award, the Waldenstrom Award (2014), the Hamdan Award (2016), and election to the American Society of Clinical Investigation (2016).

“Through the use of technologies like 3-D cell cultures – organoids —  nd gene editing tools like CRISPR, I believe CSHL will accelerate the drug discovery and development process.  I’m very hopeful that five … Continue reading Tuveson Heads Cold Spring Harbor; COH, TGen Form Collaboration

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2018 The Cancer Letter Inc.